vTv Therapeutics Inc.
VTVT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VTVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates for metabolic and inflammatory diseases, with its lead program cadisegliatin (TTP399) in Phase 3 for type 1 diabetes.
Key risk: No revenue or approved products
BioSniper Score
Based on 5 of 6 signals
Market Cap
$127.9M
Cash Runway
22.8 moLead Asset
cadisegliatin (Phase 3)
Next Catalyst
Phase3_Topline · May 1, 2027Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for vTv Therapeutics Inc..
Similar companies
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates for metabolic and inflammatory diseases, with its lead program cadisegliatin (TTP399) in Phase 3 for type 1 diabetes.
- Lead drug candidate cadisegliatin (TTP399) is being evaluated in a Phase 3 trial as adjunctive therapy in type 1 diabetes, with topline data expected in 2027-05-01 [sec_mda · as of 2026-08-06].
- As of 2026-06-30, the company reported cash & equivalents of $86.6M, no revenue, and a net loss of $13.1M for the period [sec].
- The company has not generated any revenue from drug product sales and does not expect to until regulatory approval and commercialization of a drug candidate [sec_mda · as of 2026-08-06].
- vTv expects to need substantial additional funding to continue operations and development activities, including ongoing clinical trials [sec_mda · as of 2026-05-13].
What works
- Lead candidate cadisegliatin is in a Phase 3 trial for type 1 diabetes, a large market with significant unmet need, and topline data is anticipated in 2027-05-01 [sec_mda · as of 2026-08-06].
- The company raised $51.0 million in a private placement financing in 2024, providing capital to advance its lead program [sec_mda · as of 2025-03-20].
- Cash position of $86.6M as of 2026-06-30 provides a runway to fund operations into the near term, including the Phase 3 readout [sec].
What to weigh
- The company has no approved products and has never generated revenue from drug sales, with no expectation of revenue until potential regulatory approval [sec_mda · as of 2026-08-06].
- vTv has a history of net losses, reporting a net loss of $13.1M for the six months ended 2026-06-30 [sec].
- The company anticipates needing substantial additional funding to continue operations, and there is no guarantee of future financing [sec_mda · as of 2026-05-13].
- Clinical development is highly uncertain, and the company cannot reasonably estimate the timing or costs to complete development of any drug candidate [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
Company has no revenue from drug product sales
“To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2027-05-01 · Phase3_Topline — Phase 3 Topline: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo- — Topline results from the Phase 3 trial will determine whether cadisegliatin meets its efficacy and safety endpoints, a key value inflection point for the company.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — Company has never generated drug product revenue and may never do so without regulatory approval [sec_mda · as of 2026-08-06].
- Need for substantial additional funding — vTv expects to need more capital to continue operations and development, with no guarantee of availability [sec_mda · as of 2026-05-13].
- Clinical trial uncertainty — Phase 3 trial results for cadisegliatin are uncertain; failure would significantly impact the company's prospects [sec_mda · as of 2026-05-13].
- History of net losses — Company reported a net loss of $13.1M for the six months ended 2026-06-30, with losses expected to continue [sec].
What to watch
- Phase 3 topline data for cadisegliatin in type 1 diabetes, expected in 2027-05-01 [sec_mda · as of 2026-08-06].
- Any financing activities or capital raises to fund ongoing operations and development [sec_mda · as of 2026-05-13].
- Regulatory updates or interactions with the FDA regarding cadisegliatin or other pipeline candidates [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run vTv Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available vTv Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
22.8 months
D/E 0.11
Lead: Phase 3
1 candidate
1 upcoming, next in ~244d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$51.3M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 298,496 | $11.8M |
| fmr llc | 260,391 | $10.3M |
| vanguard capital management llc | 217,844 | $8.6M |
| millennium management llc | 206,288 | $8.2M |
| baker bros. advisors lp | 148,314 | $5.9M |
| geode capital management, llc | 32,886 | $1.3M |
| northern trust corp | 18,052 | $716K |
| vanguard fiduciary trust co | 16,126 | $640K |
| 683 capital management, llc | 16,000 | $635K |
| marshall wace, llp | 13,389 | $531K |
Showing top 10 of 33 institutional holders of vTv Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 4.6%
- Days to cover
- 2.3
- Shares short
- 112,740
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VTVT short interestGovernance
Frequently asked questions
What is the AI investment thesis for vTv Therapeutics Inc.?
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates for metabolic and inflammatory diseases, with its lead program cadisegliatin (TTP399) in Phase 3 for type 1 diabetes.
What is vTv Therapeutics Inc.'s lead drug candidate?
vTv Therapeutics Inc.'s most advanced tracked candidate is cadisegliatin (Phase 3) for Diabetes Mellitus, Type 1; Type 1 Diabetes (T1D).
What is vTv Therapeutics Inc.'s next catalyst?
vTv Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-" — expected May 1, 2027.
Who is the CEO of vTv Therapeutics Inc.?
Mr. Paul J. Sekhri is the chief executive officer of vTv Therapeutics Inc. (VTVT).
Where is vTv Therapeutics Inc. headquartered?
vTv Therapeutics Inc. (VTVT) is headquartered in High Point, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.